Guggenheim Assumes Xenon Pharmaceuticals at Buy, Announces Price Target of $73

Benzinga Newsdesk www.benzinga.com Neutral 50.4%

Neg 0% Neu 50.4% Pos 0%

Guggenheim analyst Delma Caiati assumes Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy rating and announces Price Target of $73.